Prevalence of mpox viral DNA in cutaneous specimens of monkeypox-infected patients: a systematic review and meta-analysis.
cutaneous
infectivity potential
meta-analysis
monkeypox
mpox viral DNA
skin lesion
transmission
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
04
2023
accepted:
05
05
2023
medline:
18
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Human monkeypox (mpox) disease is a multicountry outbreak driven by human-human transmission which has resulted in an international public health emergency. However, there is limited evidence on the positivity rate of skin lesions for mpox viral DNA. We aim to fill this gap by estimating the pooled positivity rate of skin samples with mpox viral DNA from mpox patients globally. In this systematic review and meta-analysis, seven databases and several preprint servers have been extensively searched until 17 January 2023 according to a prospectively registered protocol (PROSPERO: CRD42023392505). Articles including the positivity rate of skin samples with mpox viral DNA in mpox-confirmed patients were considered eligible. After a quality assessment, a random-effect meta-analysis was used for pooled prevalence. To explore and resolve heterogeneity, we used statistical methods for outlier detection, influence analysis, and sensitivity analysis. Among the 331 articles retrieved after deduplication, 14 studies were finally included. The pooled positivity rate of the skin samples was 98.77% (95% CI: 94.74%-99.72%). After the removal of an influential outlier, The present findings reinforce that skin lesions act as a reservoir of mpox viral DNA and contribute to a high infectivity risk. This may be a prevailing basis of prompt transmission during the current multicountry outbreak and also needs further investigation. The present imperative outcome may benefit in producing valuable preventive and management procedures in an appropriate health strategy.
Sections du résumé
Background
Human monkeypox (mpox) disease is a multicountry outbreak driven by human-human transmission which has resulted in an international public health emergency. However, there is limited evidence on the positivity rate of skin lesions for mpox viral DNA. We aim to fill this gap by estimating the pooled positivity rate of skin samples with mpox viral DNA from mpox patients globally.
Methods
In this systematic review and meta-analysis, seven databases and several preprint servers have been extensively searched until 17 January 2023 according to a prospectively registered protocol (PROSPERO: CRD42023392505). Articles including the positivity rate of skin samples with mpox viral DNA in mpox-confirmed patients were considered eligible. After a quality assessment, a random-effect meta-analysis was used for pooled prevalence. To explore and resolve heterogeneity, we used statistical methods for outlier detection, influence analysis, and sensitivity analysis.
Findings
Among the 331 articles retrieved after deduplication, 14 studies were finally included. The pooled positivity rate of the skin samples was 98.77% (95% CI: 94.74%-99.72%). After the removal of an influential outlier,
Conclusion/interpretation
The present findings reinforce that skin lesions act as a reservoir of mpox viral DNA and contribute to a high infectivity risk. This may be a prevailing basis of prompt transmission during the current multicountry outbreak and also needs further investigation. The present imperative outcome may benefit in producing valuable preventive and management procedures in an appropriate health strategy.
Identifiants
pubmed: 37457957
doi: 10.3389/fcimb.2023.1179885
pmc: PMC10349178
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1179885Informations de copyright
Copyright © 2023 Rani, Goyal, Shamim, Satapathy, Pal, Squitti, Goswami, Sah, Barboza and Padhi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Environ Res Public Health. 2022 Sep 17;19(18):
pubmed: 36141993
Bull World Health Organ. 1972;46(5):593-7
pubmed: 4340218
Vaccines (Basel). 2022 Dec 06;10(12):
pubmed: 36560493
Lancet Infect Dis. 2023 Apr;23(4):445-453
pubmed: 36521505
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Lancet Infect Dis. 2022 Aug;22(8):1153-1162
pubmed: 35623380
Lancet Reg Health Am. 2022 Dec 13;17:100406
pubmed: 36776570
Euro Surveill. 2022 Jul;27(28):
pubmed: 35837964
Int J Infect Dis. 2023 Feb;127:150-161
pubmed: 36470502
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Pathogens. 2023 Mar 14;12(3):
pubmed: 36986374
PLoS One. 2011 Jan 18;6(1):e15615
pubmed: 21267444
Clin Infect Dis. 2009 Jan 1;48(1):e6-8
pubmed: 19025497
J Clin Microbiol. 2023 Jan 26;61(1):e0136522
pubmed: 36598196
N Engl J Med. 2022 Aug 25;387(8):679-691
pubmed: 35866746
Travel Med Infect Dis. 2022 Sep-Oct;49:102425
pubmed: 35963557
Pathogens. 2023 Jan 15;12(1):
pubmed: 36678494
Asian J Psychiatr. 2023 Jun;84:103550
pubmed: 36958229
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Lancet. 2022 Aug 27;400(10353):661-669
pubmed: 35952705
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
Lancet Infect Dis. 2023 Jan;23(1):74-80
pubmed: 36183707
Am J Orthod Dentofacial Orthop. 2020 Apr;157(4):586-588
pubmed: 32241366
J Med Virol. 2023 Jan;95(1):e28276
pubmed: 36326021
Clin Infect Dis. 2023 Apr 3;76(7):1311-1314
pubmed: 36370091
EClinicalMedicine. 2023 Feb;56:101817
pubmed: 36628187
Int J Evid Based Healthc. 2018 Dec;16(4):195-203
pubmed: 29621038
Infection. 2023 Feb;51(1):265-270
pubmed: 35816222
Travel Med Infect Dis. 2022 Nov-Dec;50:102448
pubmed: 36087645
MMWR Morb Mortal Wkly Rep. 2022 Nov 04;71(44):1407-1411
pubmed: 36331124
Clin Infect Dis. 2005 Dec 15;41(12):1742-51
pubmed: 16288398
Clin Microbiol Infect. 2023 Feb;29(2):233-239
pubmed: 36028090
Br J Dermatol. 2022 Nov;187(5):765-772
pubmed: 35917191
Euro Surveill. 2022 Aug;27(33):
pubmed: 35983771
Emerg Infect Dis. 2022 Dec;28(12):2513-2515
pubmed: 36223653
Exp Dermatol. 2023 Feb;32(2):198-202
pubmed: 36222009
J Clin Virol. 2022 Oct;155:105254
pubmed: 36057206
Lancet. 2022 Dec 3;400(10367):1953-1965
pubmed: 36403584